Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Elite Pharma Inc (ELTP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 72,359
  • Shares Outstanding, K 820,400
  • Annual Sales, $ 7,460 K
  • Annual Income, $ -3,670 K
  • 36-Month Beta 0.84
  • Price/Sales 9.77
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/08/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0691 +27.35%
on 12/27/18
0.0900 -2.22%
on 01/17/19
+0.0132 (+17.65%)
since 12/21/18
3-Month
0.0691 +27.35%
on 12/27/18
0.1050 -16.19%
on 11/20/18
+0.0080 (+10.00%)
since 10/23/18
52-Week
0.0691 +27.35%
on 12/27/18
0.1449 -39.27%
on 01/30/18
-0.0215 (-19.63%)
since 01/23/18

Most Recent Stories

More News
Elite Pharmaceuticals and SunGen Pharma File ANDA for an Antibiotic

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it filed an Abbreviated...

ELTP : 0.0880 (-0.23%)
Elite Pharmaceuticals and SunGen Pharma Receive FDA Approval for Generic Adderall(R)

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it received approval...

ELTP : 0.0880 (-0.23%)
Elite Pharmaceuticals Receives FDA Approval for Hydrocodone and Acetaminophen Combo

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it received...

ELTP : 0.0880 (-0.23%)
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2019 Ended September 30, 2018 and Provides Conference Call Information

Conference Call Scheduled for Monday, November 12 at 11:30 AM EST

ELTP : 0.0880 (-0.23%)
Elite Pharmaceuticals Launches Generic Methadone Tablets

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced the commercial launch...

ELTP : 0.0880 (-0.23%)
Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today reported positive topline results...

ELTP : 0.0880 (-0.23%)
Elite Pharmaceuticals Files ANDA for Codeine and Acetaminophen Combo

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it has filed...

ELTP : 0.0880 (-0.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade ELTP with:

Key Turning Points

2nd Resistance Point 0.0925
1st Resistance Point 0.0903
Last Price 0.0880
1st Support Level 0.0844
2nd Support Level 0.0807

See More

52-Week High 0.1449
Fibonacci 61.8% 0.1159
Fibonacci 50% 0.1070
Fibonacci 38.2% 0.0981
Last Price 0.0880
52-Week Low 0.0691

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar